Evotec AG and Aspireo Pharmaceuticals have entered into a strategic advisory agreement to support the development and partnering of Aspireo’s Somatoprim (DG3173), a new molecular entity analogue currently in Phase I development. Somatostatin analogues have been approved for the treatment of acromegaly, carcinoid tumors, and Cushing’s disease, and have demonstrated significant potential in diabetic retinopathy.    Evotec will provide strategic and operational advice on the partnering ...